52
IRUS Total
Downloads
  Altmetric

Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure

Title: Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure
Authors: Ferreira, JP
Rossignol, P
Pizard, A
Machu, J-L
Collier, T
Girerd, N
Huby, A-C
Gonzalez, A
Diez, J
López, B
Sattar, N
Cleland, JG
Sever, PS
Zannad, F
Item Type: Journal Article
Abstract: BACKGROUND: An increase in myocardial collagen content may contribute to the development of heart failure; this might be inhibited or reversed by mineralocorticoid receptor antagonists (MRAs). We investigated changes in serum concentrations of the collagen synthesis biomarkers N-terminal propeptide of procollagen type III (PIIINP) (primary outcome) and C-terminal propeptide of procollagen type I (PICP) (secondary outcome) after non-randomised initiation of spironolactone as add-on therapy among patients with resistant hypertension enrolled in the 'Anglo-Scandinavian Cardiac Outcomes' trial (ASCOT). METHODS: An age/sex matching plus propensity-scored logistic regression model incorporating variables related to the outcome and spironolactone treatment was created to compare patients treated with spironolactone for a 9-month period versus matched controls. A within-person analysis comparing changes in serum biomarker concentrations in the 9 months before versus after spironolactone treatment was also performed. RESULTS: Patients included in the between-person analysis (n=146) were well matched: the mean age was 63±7 years and 11% were woman. Serum concentrations of PIIINP and PICP rose in 'controls' and fell during spironolactone treatment (adjusted means +0.52 (-0.05 to 1.09) vs -0.41 (-0.97 to 0.16) ng/mL, p=0.031 for PIIINP and +4.54(-1.77 to 10.9) vs -6.36 (-12.5 to -0.21) ng/mL, p=0.023 for PICP). For the within-person analysis (n=173), spironolactone treatment was also associated with a reduction in PICP (beta estimate=-11.82(-17.53 to -6.10) ng/mL, p<0.001) but not in PIIINP levels. CONCLUSIONS: Treatment with spironolactone was associated with a reduction in serum biomarkers of collagen synthesis independently of blood pressure in patients with hypertension, suggesting that spironolactone might exert favourable effects on myocardial collagen synthesis and fibrosis. Whether this effect might contribute to slowing the progression to heart failure is worth investigating.
Issue Date: 29-Jan-2019
Date of Acceptance: 26-Jul-2018
URI: http://hdl.handle.net/10044/1/62840
DOI: http://dx.doi.org/10.1136/heartjnl-2018-313182
ISSN: 1355-6037
Publisher: BMJ Publishing Group
Start Page: 307
End Page: 314
Journal / Book Title: Heart
Volume: 105
Issue: 4
Copyright Statement: © Author(s) (or their employer(s)) 2018. No commercial re-use. See rights and permissions. Published by BMJ. This article has been accepted for publication in Heart following peer review. The definitive copyedited, typeset version Ferreira JP, Rossignol P, Pizard A, et alPotential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressureHeart 2019;105:307-314 is available online at: http://dx.doi.org/10.1136/heartjnl-2018-313182
Sponsor/Funder: Foundation for Circulatory Health
National Institute for Health Research
National Institute for Health Research
Funder's Grant Number: Nil
NF-SI-0513-10059
NF-SI-0513-10059
Keywords: Science & Technology
Life Sciences & Biomedicine
Cardiac & Cardiovascular Systems
Cardiovascular System & Cardiology
hypertension
heart failure
EXTRACELLULAR-MATRIX TURNOVER
ELEVATION MYOCARDIAL-INFARCTION
HEART-FAILURE INSIGHTS
DOUBLE-BLIND
DILATED CARDIOMYOPATHY
CROSS-LINKING
FIBROSIS
EPLERENONE
TRIAL
DYSFUNCTION
heart failure
hypertension
heart failure
hypertension
Cardiovascular System & Hematology
1102 Cardiorespiratory Medicine and Haematology
Publication Status: Published online
Conference Place: England
Online Publication Date: 2018-08-18
Appears in Collections:National Heart and Lung Institute